Key Takeaways
- Elevance Health delivered Q2 adjusted EPS of $7.45, surpassing consensus estimates of $6.21 by $1.24
- Quarterly revenue totaled $49.8 billion, exceeding analyst expectations of $48.63 billion
- Operating margin contracted to 3.5% compared to 4.9% in the year-ago period, triggering investor concerns
- Shares of ELV tumbled over 9% in premarket trading despite beating earnings projections
- Company increased full-year adjusted EPS outlook to a minimum of $27.00, up from prior guidance of $26.75
Elevance Health significantly outperformed Wall Street’s second-quarter earnings projections on Wednesday, yet shares plummeted as market participants focused on deteriorating profit margins.
Shares of ELV tumbled more than 9% during premarket hours following the earnings release. The stock had rallied nearly 22% year-to-date through the announcement, finishing Monday’s session at $426.79.
The health insurance giant posted adjusted earnings of $7.45 per share, comfortably beating Wall Street’s consensus forecast of $6.21 by $1.24. Quarterly revenue hit $49.8 billion, representing a 0.8% year-over-year increase and topping the Street’s $48.63 billion projection.
Despite the strong topline and bottom-line performance, market sentiment soured quickly. The company’s operating margin compressed to 3.5% from 4.9% in the corresponding quarter last year. Adjusted operating margin similarly declined, sliding from 5.0% to 3.6%.
Within the critical Health Benefits division, the margin situation proved even more concerning. Operating margin in that segment contracted to 2.1% versus 3.8% in the prior-year period.
The benefit expense ratio climbed 80 basis points year-over-year, reaching 89.7%. Rising medical expenses within government programs fueled this expansion, though stronger performance in Individual ACA plans provided some counterbalance to the cost pressures.
Outlook Receives Modest Upgrade
Elevance bumped up its full-year adjusted EPS forecast to a minimum of $27.00, an increase from the previous floor of $26.75. This new guidance edges slightly above the Street’s consensus estimate of $26.91. The company also elevated its operating cash flow projection to no less than $6.0 billion.
This represents the second time in recent months the insurer has boosted its outlook. Following an April increase, the company confirmed the guidance again in June before this latest raise.
CEO Gail Boudreaux commented that the results “exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
Member Enrollment Declines
Medical membership totaled approximately 44.9 million as of June 30, 2026, representing a decrease of 469,000 members from the previous quarter. The reduction stemmed from a commercial fee-based customer transition along with anticipated attrition across Individual ACA and Medicaid plans.
The Health Benefits division generated $42.7 billion in quarterly revenue, reflecting 3% year-over-year growth. Meanwhile, Carelon revenue expanded 6% to reach $19.2 billion.
Wall Street sentiment entering the report had been generally positive. TD Cowen analyst Ryan Langston elevated his price target on Elevance from $400 to $465 just Tuesday. Cantor Fitzgerald similarly increased its target from $400 to $450.
Medicaid margin performance continues to draw scrutiny from investors. CFO Mark Kaye indicated during a Goldman Sachs healthcare conference in June that expenses in this segment remained elevated, with management targeting a full-year margin around -1.75%.
UBS analyst A.J. Rice characterized this margin target as “conservative,” indicating potential upside opportunity.
Elevance’s earnings arrive one day ahead of UnitedHealth Group, the industry’s largest competitor, which releases quarterly results Thursday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
